SAT0271 Continued Improvement of Signs and Symptoms in Ustekinumab-Treated Patients with Active Psoriatic Arthritis: Week 52 Results of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study

A Kavanaugh,L Puig,S Li,A B Gottlieb,C Ritchlin,I B Mcinnes,P Rahman,Y Wang,A Mendelsohn,M Doyle

doi:10.1136/annrheumdis-2013-eular.1996

SAT0271 Continued Improvement of Signs and Symptoms in Ustekinumab-Treated Patients with Active Psoriatic Arthritis: Week 52 Results of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study

A Kavanaugh, L Puig + Show 8 more

https://doi.org/10.1136/annrheumdis-2013-eular.1996

Copy DOI

Journal: Annals of the Rheumatic Diseases	Publication Date: Jun 1, 2013
Citations: 1

Affiliation: University of California, San Diego, Autonomous University of Barcelona, Janssen (United States), University of Rochester, Memorial University of Newfoundland

#PBO-controlled Period #Active Psoriatic Arthritis + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

ObjectivesWe report safety & efficacy results through wk52 of PSUMMIT I, a large, multicenter, double-blind, PBO-controlled, Phase 3 trial of ustekinumab (UST) in pts with active psoriatic arthritis (PsA).MethodsAdult PsA...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of the Rheumatic Diseases

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.